(19)
(11) EP 2 271 318 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.01.2013 Bulletin 2013/01

(45) Mention of the grant of the patent:
28.11.2012 Bulletin 2012/48

(21) Application number: 09730701.1

(22) Date of filing: 09.04.2009
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
 A61K 31/165(2006.01)
(86) International application number:
PCT/GB2009/050353
(87) International publication number:
WO 2009/125226 (15.10.2009 Gazette 2009/42)

(54)

PHARMACEUTICAL DEPOT COMPRISING N-{5-[(CYCLOPROPYLAMINO) CARBONYL]-2-METHYLPHENYL}-3-FLUORO-4- (PYRIDIN-2-YLMETHOXY) BENZAMIDE

PHARMAZEUTISCHES DEPOT MIT N-{5-[(CYCLOPROPYLAMINO) CARBONYL]-2-METHYLPHENYL}-3-FLUOR-4- (PYRIDIN-2-YLMETHOXY)-BENZAMID

PRODUIT PHARMACEUTIQUE RETARD COMPRENANT DU N-{5-[(CYCLOPROPYLAMINO)CARBONYL]-2-MÉTHYLPHÉNYL}-3-FLUORO-4-(PYRIDIN-2-YLMÉTHOXY)BENZAMIDE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA RS

(30) Priority: 09.04.2008 US 43491

(43) Date of publication of application:
12.01.2011 Bulletin 2011/02

(73) Proprietor: AstraZeneca AB
151 85 Södertälje (SE)

(72) Inventors:
  • BATEMAN, Nicola, Frances
    Cheshire SK10 2NA (GB)
  • MACFAUL, Philip, Alexander
    Cheshire SK10 4TG (GB)
  • NASH, Ian, Alun
    Cheshire SK10 4TG (GB)

(74) Representative: Greaves, Carol Pauline et al
Greaves Brewster LLP Copa House Station Road
Cheddar, BS27 3AH
Cheddar, BS27 3AH (GB)


(56) References cited: : 
WO-A-2005/061465
 US-A1- 2007 251 530
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).